Name | Aroostook Health Center |
---|---|
Location | Po Box 410, Mars Hill, Maine |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 72 |
Occupancy Rate | 57.64% |
Medicare ID (CCN) | 205018 |
Legal Business Name | Aroostook Medical Center |
Ownership Type | Non Profit - Corporation |
NPI Number | 1396864336 |
Organization Name | AROOSTOOK MEDICAL CENTER |
Doing Business As | NORTHERN LIGHT CONTINUING CARE, MARS HILL |
Address | 15 Highland Avenue, Mars Hill, ME 04758 |
Phone Number | 207-768-4915 |
News Archive
Tarix Pharmaceuticals today announced that it's drug, TXA127, has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as a treatment to enhance engraftment in patients receiving a stem cell transplant. TXA127 has also received Orphan Drug designation for the treatment of Myelodysplastic Syndrome (MDS).
Lung Cancer Alliance called again today for a comprehensive plan of action that will make reducing lung cancer mortality a public health priority.
Rutgers is one of seven institutions in the country selected by the National Institutes of Health to receive this year's BEST Award - a $2 million grant designed to expose many of the university's most promising biomedical sciences graduate trainees to career opportunities that go beyond the academic path that they have traditionally taken.
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.
› Verified 3 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Tarix Pharmaceuticals today announced that it's drug, TXA127, has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as a treatment to enhance engraftment in patients receiving a stem cell transplant. TXA127 has also received Orphan Drug designation for the treatment of Myelodysplastic Syndrome (MDS).
Lung Cancer Alliance called again today for a comprehensive plan of action that will make reducing lung cancer mortality a public health priority.
Rutgers is one of seven institutions in the country selected by the National Institutes of Health to receive this year's BEST Award - a $2 million grant designed to expose many of the university's most promising biomedical sciences graduate trainees to career opportunities that go beyond the academic path that they have traditionally taken.
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.
› Verified 3 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 18.18 | 14.46 |
Percentage of long-stay residents who lose too much weight | 6.74 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 60 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.43 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 7.85 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 6.19 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 91.75 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 38.34 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 84.37 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 1.89 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 19.58 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 23.76 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 8 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.89 | 95.98 |
Percentage of short-stay residents who made improvements in function | 78.17 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 90.14 | 82.93 |
News Archive
Tarix Pharmaceuticals today announced that it's drug, TXA127, has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as a treatment to enhance engraftment in patients receiving a stem cell transplant. TXA127 has also received Orphan Drug designation for the treatment of Myelodysplastic Syndrome (MDS).
Lung Cancer Alliance called again today for a comprehensive plan of action that will make reducing lung cancer mortality a public health priority.
Rutgers is one of seven institutions in the country selected by the National Institutes of Health to receive this year's BEST Award - a $2 million grant designed to expose many of the university's most promising biomedical sciences graduate trainees to career opportunities that go beyond the academic path that they have traditionally taken.
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.
› Verified 3 days ago